Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXeros Tech Regulatory News (XSG)

Share Price Information for Xeros Tech (XSG)

Share Price is delayed by 15 minutes
Get Live Data
1.45    0.05 (3.45%)
Bid:
1.40
Ask:
1.50
Spread: 0.10 (7.143%)
Market Cap: £12.93m
XSG Live PriceLast checked at - London Stock Exchange

Intraday Xeros Tech Share Chart

Board Change

18 Mar 2022 07:00

RNS Number : 2093F
Xeros Technology Group plc
18 March 2022
 

18 March 2022

 

Xeros Technology Group plc

 

Board change

 

Xeros Technology Group plc (AIM: XSG, 'the Group', 'Xeros'), the licensor of proprietary solutions improving the sustainability and economics of garments and fabrics, announces today that Mark Nichols, CEO, has advised the Board that he wishes to leave Xeros to transition to a portfolio career at the end of 2022.

 

The Company is now at a point in time where it has successfully completed the development of its two platform technologies, secured broad IP protection and has entered into initial licensing agreements for both. In Mark's view, the Company would now benefit from new leadership to deliver on the next phase of its growth journey. Mark will remain with the business until 30 September 2022 to oversee the Group's ongoing commercialisation process and has committed to a comprehensive and orderly handover to his successor, for whom a search process is now underway.

As part of the above arrangements and in recognition of his contribution to the business over his six and half years of service, his status as a "good leaver" under the terms of the Company's EMI Share Option Scheme ("EMI Scheme") and Unapproved Share Option Scheme ("Unapproved Scheme") (together, the "Schemes") and to properly incentivise Mr Nichols during the transition period, the Remuneration Committee has determined:

 

1) to allow Mr Nichols to keep all outstanding options granted to him in 2020, 2021 and 2022 under the terms of the Schemes; and

2) to waive all unsatisfied performance criteria attaching to those options.

 

Discretion to do so is permitted under the terms of the Schemes.

 

The Remuneration Committee has further determined to allow the retained options to remain capable of exercise for a further three and a half years from his leaving date. This discretion is available to the Company's Remuneration Committee in respect of the EMI Scheme though is not so under the terms of the Unapproved Scheme. Accordingly, the Board (excluding Mr Nichols) is proposing to amend the terms of the option agreements granted to Mr Nichols under the Unapproved Scheme to allow such discretion to be taken. This amendment is deemed to be a related party transaction for the purposes of the AIM Rules. The Board (excluding Mr Nichols) having consulted with finnCap (as the Company's nominated adviser) consider that the terms of such proposed amendment are fair and reasonable insofar as the Company's shareholders are concerned.

 

Mr Nichols has agreed to cancel the options granted to him over a total of 18,901 ordinary shares of 15p each ("Ordinary Shares") in 2015, 2017 and 2018 which have an exercise price of £210 or £225 per share.

 

After allowing for the cancellation of the options granted in 2015, 2017 and 2018, Mr Nichols will hold options over a total of 415,246 Ordinary Shares (EMI Scheme: 246,200; Unapproved Share Option scheme: 169,046).

 

Klaas de Boer, Chairman of Xeros, said:

 

"After six and a half years of leading the development of Xeros we accept Mark's desire for a career change and fully appreciate his reasoning for it. The Company is now poised at the commercialisation stage of its development and Mark will leave the business very well positioned to grow significantly over the next 3+ years in partnership with global brands and manufacturers. They have the reach to deliver the benefits of our technologies to businesses and consumers across the globe. The Board has commenced the search for a new leader with the relevant skills and experience to complete a comprehensive commercialisation strategy for our exciting platform technologies."

 

This announcement contains inside information for the purposes of Market Abuse Regulation (Regulation (EU) No. 596/2014) as retained and applicable in the UK pursuant to S3 of the European Union (Withdrawal) Act 2018 ('MAR').

 

 

Enquiries:

Xeros Technology Group plc

Klaas de Boer, Chairman

Paul Denney, Chief Financial Officer

Tel: 0114 321 6328

 

finnCap Limited (Nominated Adviser and Broker)

Julian Blunt/Teddy Whiley, Corporate Finance

Andrew Burdis/Sunila de Silva, ECM

Tel: 020 7220 0570

Notes to Editors

 

With close to 40 patent families, Xeros' revolutionary platform technologies, XTend™ and XFiltra™ set new standards for performance and sustainability across our clothing's lifecycle. By reducing the consumption of valuable natural resources and preventing microfibre and microplastic pollution, Xeros greatly reduces the impact of our clothes on the planet.

Backed by science, we set new standards for significantly reduced water consumption, lower carbon and effluent emissions, and improved garment care/life at the manufacturing stage and throughout laundry processes, in industry, and in the home. Xeros' technologies deliver a unique combination of unbeatable sustainability outcomes, improving performance whilst reducing costs. 

The manufacture of clothes and their subsequent care consumes vast amounts of our finite, valuable resources. Xeros licenses new technologies to enable us all to consume less, helping to protect the world for our future. 

For more information, please visit - http://www.xerostech.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAJRMMTMTIBTRT
Date   Source Headline
28th Apr 20267:00 amRNSFull Year Results 2025
21st Apr 20267:00 amRNSNotice of Results and Online Presentation
5th Mar 20267:00 amRNSPurchase Order ahead of European Launch of XF3
11th Feb 202610:39 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSBoard Change
27th Jan 20267:00 amRNSTrading Update
7th Jan 20262:52 pmRNSTR-1 First Equity
2nd Jan 202611:46 amRNSBlock listing Interim Review
11th Dec 20251:06 pmRNSTR-1 Entrepreneurs Fund
2nd Dec 20254:48 pmRNSTR-1 Lombard Odier
2nd Dec 20252:26 pmRNSTR-1 Dowgate
2nd Dec 202511:10 amRNSTR-1 Maven
28th Nov 202511:02 amRNSResults of General Meeting and Director Dealings
27th Nov 202512:28 pmRNSResult of Follow-on Subscription and TVR
26th Nov 20254:44 pmRNSTR-1 Spreadex
11th Nov 20251:14 pmRNSResult of Retail Offer
7th Nov 202510:15 amRNSResult of Fundraising
7th Nov 20257:00 amRNSRetail Offer
6th Nov 20256:32 pmRNSProposed Fundraise
24th Oct 20253:07 pmRNSBlock listing Interim Review
14th Oct 20255:11 pmRNSTR-1 Maven
10th Oct 20255:20 pmRNSTR-1 Dowgate
9th Oct 20252:05 pmRNSTR-1 Spreadex
9th Oct 202511:04 amRNSTR-1 First Equity
8th Oct 20257:00 amRNSBreakthrough Launch Agreement
1st Oct 20252:08 pmRNS-RInterim Results 2025 Online Presentation
30th Sep 20257:00 amRNSInterim Results 2025
15th Sep 20256:07 pmRNSTR-1 Dowgate
12th Sep 20251:03 pmRNSTR-1 Dowgate
5th Aug 202512:13 pmRNSTR-1 First Equity
7th Jul 20252:33 pmRNSTR-1 Spreadex
19th Jun 20251:46 pmRNSResult of AGM
5th Jun 202510:11 amRNSCorrection - Application for Block Listing
4th Jun 202510:00 amRNSApplication for Block Listing
29th May 20252:43 pmRNSTR-1 Spreadex
28th May 20253:32 pmRNSTR-1 First Equity
28th May 20252:31 pmRNSTR-1 Spreadex
27th May 20252:37 pmRNSNotice of AGM and Posting of Annual Report
20th May 20257:00 amRNSFull Year Results 2024 and Trading Update
9th May 202511:08 amRNSTR-1 Spreadex
7th May 20257:00 amRNSNotice of Results and Online Presentation
6th May 202510:10 amRNSTR-1 Maven Capital
2nd May 20254:00 pmRNSTR-1 Spreadex
1st May 20254:35 pmRNSTR-1 - First Equity
31st Mar 20257:00 amRNSGrant of Options
7th Mar 202512:56 pmRNSTR-1 Spreadex
17th Feb 20252:18 pmRNSTR-1 Spreadex
17th Feb 202511:07 amRNSTR-1 First Equity
13th Feb 202512:05 pmRNSTR-1 Spreadex
13th Feb 202510:21 amRNSTR-1 First Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.